Tert-butyl-[1-(5-fluoro-4-oxo-3-phenylquinazolin-2-yl)propyl]carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Tert-butyl-[1-(5-fluoro-4-oxo-3-phenylquinazolin-2-yl)propyl]carbamic acid
• 英文别名: tert-butyl-[1-(5-fluoro-4-oxo-3-phenylquinazolin-2-yl)propyl]carbamic acid
• 化学式: C₂₂H₂₄FN₃O₃
• 分子量: 397.4
• InChiKey: KZBQRNFVMVTISB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  73.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB AND ITS PREMIX<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION D'IDÉLALISIB AMORPHE ET SON MÉLANGE PRÉLIMINAIRE
  申请人：MYLAN LABORATORIES LTD

  公开号：WO2016147206A1

  公开（公告）日：2016-09-22

  Processes for the preparation of amorphous idelalisib are provided. Processes for the preparation of a premix of amorphous idelalisib are also provided.

  提供了制备非晶态idelalisib的过程。还提供了制备非晶态idelalisib预混物的过程。
• SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
  申请人：CALITOR SCIENCES, LLC

  公开号：US20160318913A1

  公开（公告）日：2016-11-03

  The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
• Process for the Preparation of Amorphous Idelalisib and its Premix
  申请人：Mylan Laboratories Ltd

  公开号：US20180064714A1

  公开（公告）日：2018-03-08

  Processes for the preparation of amorphous idelalisib are provided. Processes for the preparation of a premix of amorphous idelalisib are also provided.
• US9518046B2
  申请人：——

  公开号：US9518046B2

  公开（公告）日：2016-12-13
• [EN] SUBSTITUTED 2-AMINO PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE À SUBSTITUTION 2-AMINO SERVANT DE COMPOSÉS INHIBITEURS DE KINASE
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2014106800A2

  公开（公告）日：2014-07-10

  The present invention provides novel substituted 2-amino pyrimidine derivatives kinase enzyme inhibitor compounds of formula (1), which may be therapeutically useful kinase inhibitor, more particularly PI3K inhibitors. Formula (1) in which A, R1, R2 R3. R4, Q and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts and stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly PI3K enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.